Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology

Abstract

Vaccinia-based systems have been extensively explored for the development of recombinant vaccines. Herein we describe an innovative vaccinia virus (VACV)-derived vaccine platform technology termed Sementis Copenhagen Vector (SCV), which was rendered multiplication-defective by targeted deletion of the essential viral assembly gene D13L. A SCV cell substrate line was developed for SCV vaccine production by engineering CHO cells to express D13 and the VACV host-range factor CP77, because CHO cells are routinely used for manufacture of biologics. To illustrate the utility of the platform technology, a SCV vaccine against chikungunya virus (SCV-CHIK) was developed and shown to be multiplication-defective in a range of human cell lines and in immunocompromised mice. A single vaccination of mice with SCV-CHIK induced antibody responses specific for chikungunya virus (CHIKV) that were similar to those raised following vaccination with a replication-competent VACV-CHIK and able to neutralize CHIKV. Vaccination also provided protection against CHIKV challenge, preventing both viremia and arthritis. Moreover, SCV retained capacity as an effective mouse smallpox vaccine. In summary, SCV represents a new and safe vaccine platform technology that can be manufactured in modified CHO cells, with pre-clinical evaluation illustrating utility for CHIKV vaccine design and construction.

Authors Eldi, Preethi; Cooper, Tamara H.; Liu, Liang; Prow, Natalie A.; Diener, Kerrilyn R.; Howley, Paul M.; Suhrbier, Andreas; Hayball, John D.
Journal MOLECULAR THERAPY
Pages 2332-2344
Volume 25
Date 1/10/2017
Grant ID
Funding Body Sementis Ltd.
URL http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/j.ymthe.2017.06.017